Ciprofloxacin Extended Release
In the Treatment of Urinary Tract Infections and Uncomplicated Pyelonephritis
- Waugh, John
- Keating, Gillian M
▴ Ciprofloxacin extended release (XR) is a new oral formulation of a fluoroquinolone that allows once-daily administration while maintaining therapeutic serum levels of the drug.
▴ The maximum plasma concentrations (Cmax) of once-daily ciprofloxacin XR 500mg was higher than that of twice-daily ciprofloxacin immediate release 250mg and the Cmax of once-daily ciproflocaxin XR 1000mg was higher than that of twice-daily ciprofloxacin 500mg. No accumulation of ciprofloxacin XR at steady state was observed in healthy men and all other pharmacokinetic parameters were similar to those of the immediate-release formulation.
▴ In patients with uncomplicated urinary tract infection (UTI), bacteriological eradication rates were similar in recipients of ciprofloxacin XR and immediate-release ciprofloxacin at the test-of-cure (TOC) visit, as were rates of persistence or new infection. Clinical cure rates were also similar in the two treatment groups.
▴ Bacteriological eradication occurred in 89% of ciprofloxacin XR and 85% of immediate-release ciprofloxacin recipients with complicated UTIs or acute uncomplicated pyelonephritis at the TOC visit. Clinical cure rates were also similar in the two treatment groups.
▴ Ciprofloxacin XR was generally well tolerated in patients with uncomplicated or complicated UTIs or acute uncomplicated pyelonephritis and showed similar tolerability to that of the immediate-release formulation.
